Life Science Investing Axsome Therapeutics Recognizes Mental Illness Awareness Week Along with the National Advocacy Community
Life Science Investing Axsome Therapeutics to Report Third Quarter 2025 Financial Results on November 3
Life Science Investing Axsome Therapeutics Highlights Data Across Its Leading Neuroscience Pipeline at Psych Congress 2025
Axsome Therapeutics Announces Completion of Patient Enrollment in the ASCEND Phase 2 Trial of AXS-05 in Major Depressive Disorder
Skyharbour Partner Company Terra Clean Energy Announces Fraser Lakes B Deposit Recognized by Government of Canada as Active Rare Earth Deposit
